Pharmaceutical Contract Manufacturing Market

Overview

The global Pharmaceutical Contract Manufacturing Market was valued at USD 175.0 billion in 2025 and is projected to reach USD 332.8 billion by 2034, growing at a CAGR of 7.4% during the forecast period (2026–2034). The market is driven by rising outsourcing of development and manufacturing by innovator and mid-sized drug makers, strong demand for biologics, peptides and antibody-drug conjugates that need specialized capacity, and the push to diversify pharmaceutical supply chains across regions. The market is shifting from conventional, standalone, single-service manufacturing contracts toward long-term integrated partnerships that combine development, drug substance, drug product and packaging under one provider. Drug makers are directing volume to CDMOs with proven capability in antibody-drug conjugates, GLP-1 peptides, high-potency compounds and prefilled syringes, while single-use bioreactors, continuous manufacturing and digital batch records are improving yield and shortening technology transfer. Government initiatives such as the US BIOSECURE Act, signed into law on December 18, 2025 as part of the FY2026 National Defense Authorization Act, restrict federal agencies, contractors and grant recipients from using services of designated biotechnology companies of concern. The Office of Management and Budget must publish the initial list of such companies by December 2026, and sponsors are already qualifying alternative CDMOs, which is increasing demand for capacity from unrestricted suppliers. By Region, North America held the largest share of the market in 2025 at 36%, supported by large biologics and fill-finish campuses in the United States and a deep base of innovator companies. Asia-Pacific is expected to be the fastest-growing region during the forecast period, as capacity additions across China, India, South Korea and Japan attract rising global outsourcing to cost-competitive, cGMP-compliant sites.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Rising Demand for Complex Modalities, Led by Antibody-Drug Conjugates and Peptide Therapies, Emerging as a Transformational Trend

• Sponsors are moving antibody-drug conjugates, GLP-1 peptides and other complex therapies to specialist partners equipped for highly potent payloads and solid-phase peptide synthesis. These programs need containment suites, conjugation expertise and cytotoxic handling at commercial volumes, which few in-house plants offer, so outsourcing is becoming the default route for scale-up.
• Providers are adding single-use bioreactors, continuous processing, in-line analytics and digital batch records to shorten technology transfer and improve batch consistency. Platform processes for monoclonal antibodies now let a CDMO move a candidate from cell line to clinical supply faster, giving early-stage biotechs a clear reason to avoid building their own plants.
• Leading CDMOs are bundling development, drug substance, drug product and packaging into single contracts, which raises switching costs and rewards providers with end-to-end capability. Smaller regional players are responding by specializing in niches such as high-potency oral solids, sterile injectables or peptide manufacturing, so that they stay relevant to sponsors seeking focused expertise.
• CordenPharma announced a new peptide manufacturing facility in Muttenz, Switzerland, with more than 5,000 liters of solid-phase peptide synthesis reactor capacity. The company is also expanding its Boulder, Colorado site to above 42,000 liters of reactor capacity by 2028, a clear signal of sustained outsourced demand for GLP-1 and other peptide therapies.

KEY MARKET DRIVER

Growing Pharmaceutical Outsourcing to Secure Specialized Capacity and Faster Time to Market is the Key Driver

• Building a biologics or sterile injectable plant takes several years and heavy capital, so drug makers increasingly rent proven capacity instead of owning it. Outsourcing converts fixed cost into variable cost, brings clinical and commercial supply closer, and lets sponsors keep their balance sheets focused on research and marketing rather than plant construction.
• Small and mid-sized biotechs, many of them without any manufacturing assets, now depend on CDMOs from preclinical batches to commercial launch. Large pharmaceutical companies also outsource peak demand, new product launches and non-core legacy brands, which frees internal plants for priority products and keeps utilization high across their own networks.
• Regulatory expectations such as US FDA current good manufacturing practice rules and the EU GMP Annex 1 for sterile products raise the cost of running a compliant plant. Providers that spread quality-system and inspection costs across many clients can offer sponsors a more predictable route to approval, which strengthens the case for outsourcing.
• The US FDA announced its PreCheck program, which gives builders of new domestic drug manufacturing facilities earlier regulatory engagement during design, construction and pre-production. The program, created under Executive Order 14293, is designed to shorten the path to approved US capacity and encourages CDMOs and sponsors to invest in new American sites.

KEY MARKET OPPORTUNITY

Expansion of Biologics and Biosimilar Manufacturing Hubs in Emerging Markets Creating New Revenue Streams for Contract Manufacturers

• Patent expiries on major biologics are opening a large pipeline of biosimilar programs, and most developers lack in-house cell culture capacity. CDMOs that offer cell line development, process validation and commercial supply under one contract can capture these programs from the first batch through multi-year commercial campaigns, and they gain repeat revenue as each approved biosimilar moves into routine production.
• Emerging markets in Asia-Pacific, the Middle East and Latin America are building local pharmaceutical production to reduce import dependence. Global CDMOs can enter these markets through technology transfer, joint ventures and capacity-sharing agreements, which gives them a foothold in fast-growing demand centers without heavy upfront capital. Local partners gain quality systems that shorten approval timelines.
• Cell and gene therapy, mRNA and radiopharmaceutical programs remain under-served by dedicated manufacturing capacity. Providers that invest early in viral vector, plasmid and aseptic handling expertise can secure long-duration contracts with developers who prefer to avoid the high cost of building specialized suites of their own. Early movers also become the first call for new modality programs.
• India’s Union Budget 2026-27, proposed Biopharma SHAKTI with an outlay of Rs 10,000 crore, or about USD 1.1 billion, over five years. The scheme targets biologics and biosimilar manufacturing, wider clinical trial capacity and stronger regulatory capability, creating a clear opening for CDMOs operating in India.

Pharmaceutical Contract Manufacturing Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Service

Finished Dosage Form Manufacturing Services held the largest market share in 2025 because most outsourced volume still sits in tablets, capsules, sterile injectables and other ready-to-use products that sponsors prefer not to produce in-house. Established CMOs offer validated lines, packaging interfaces and regulatory track records across the FDA, EMA and other authorities, which lowers launch risk for brand owners and generic companies alike. Product transfers add steady volume as innovators close or consolidate legacy plants and shift non-core brands to contract partners. Long-term supply agreements for commercial products give this service line stable, repeat revenue and keep it ahead of other service categories.

Drug Development Services is projected to grow at the fastest CAGR during the forecast period as sponsors, especially virtual biotechs, hand over formulation, analytical method development, process scale-up and clinical supply to partners that can carry a molecule from preclinical stage to filing. Complex candidates such as antibody-drug conjugates, peptides and cell therapies need specialized process knowledge that most developers cannot hire quickly. Integrated CDMOs also win the later commercial supply contract once a program succeeds, so providers are investing in development laboratories and pilot plants to secure projects early. Rising early-stage funding for oncology and metabolic programs keeps the development pipeline full.

Service categories include

• Finished Dosage Form Manufacturing Services (Dominating Segment)
• Drug Development Services (Highest CAGR Segment)
• Active Pharmaceutical Ingredient Manufacturing Services
• Packaging Services
• Others

Analysis by Molecule Type

Small Molecules held the largest market share in 2025 because oral solid drugs and generics still account for the bulk of global prescription volume, and most of these products rely on outsourced ingredient synthesis and tablet or capsule production. Mature chemistry routes, well-understood regulatory pathways and a deep base of qualified suppliers in Europe, India and China keep unit costs competitive. Innovator companies continue to launch new small-molecule drugs in oncology, central nervous system and metabolic care, each needing custom synthesis and commercial supply. Generic and specialty drug makers add steady volume, which supports high plant utilization across contract manufacturers.

Large Molecules is projected to grow at the fastest CAGR during the forecast period as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, recombinant proteins and cell and gene therapies take a growing share of new drug approvals. These products demand mammalian cell culture, purification and aseptic fill-finish capacity that costs far more to build than small-molecule plants, so sponsors prefer to book capacity with CDMOs. Biosimilar launches on expiring blockbuster biologics add further volume, and governments are encouraging local biologics capacity, which is pushing large investments in new sites across the United States, Europe and Asia.

Molecule Type categories include

• Small Molecules (Dominating Segment)
• Large Molecules (Highest CAGR Segment)

Analysis by Dosage Form

Oral Solid Dosage held the largest market share in 2025 because tablets and capsules remain the most widely prescribed and patient-friendly dosage forms across both branded and generic drugs. High-volume granulation, compression, coating and encapsulation lines are expensive to run at the quality level regulators expect, so many drug makers outsource them. Contract manufacturers with high-potency containment, modified-release and bioavailability-enhancement technologies such as spray-dried dispersions can serve established and new products alike. Large generic portfolios and over-the-counter brands provide predictable volumes, which keeps oral solids ahead of every other dosage form.

Injectables is projected to grow at the fastest CAGR during the forecast period as biologics, peptide drugs, vaccines and many oncology therapies can only be delivered by injection. Demand for prefilled syringes, cartridges, autoinjectors and lyophilized vials is rising, particularly for GLP-1 and monoclonal antibody products, while strict contamination-control rules for sterile manufacturing raise entry barriers for new players. Sponsors therefore lean on specialist fill-finish providers with isolator technology and validated aseptic processes. Capacity shortages in sterile filling have prompted fresh capital investment, which supports faster growth than any other dosage form.

Dosage Form categories include

• Oral Solid Dosage (Dominating Segment)
• Injectables (Highest CAGR Segment)
• Oral Liquid Dosage
• Semi-Solid Dosage
• Others

Analysis by End User

Big Pharmaceutical Companies held the largest market share in 2025 because they run the broadest product portfolios and place the largest multi-year commercial supply contracts with CDMOs. These companies outsource to add surge capacity for launches, to access specialized technologies such as antibody-drug conjugate conjugation and peptide synthesis, and to move production closer to end markets amid tariff and supply-chain risk. Their procurement teams favor providers with strong quality systems, multi-site networks and clean inspection histories, which concentrates spending with established CDMOs. Site transfers from big pharma to contract partners further expand contract value in this segment.

Small and Mid-Sized Pharmaceutical Companies is projected to grow at the fastest CAGR during the forecast period because most emerging biotechs operate without manufacturing assets and rely fully on CDMOs from first-in-human batches through commercial launch. Venture-backed programs in oncology, obesity and rare diseases need fast technology transfer and flexible batch sizes, which contract partners provide without large fixed investment. As more of these companies reach late-stage trials and approval, their orders move from small clinical lots to larger commercial campaigns. Many also prefer integrated providers, which gives CDMOs with development and commercial capability a lasting advantage.

End User categories include

• Big Pharmaceutical Companies (Dominating Segment)
• Small and Mid-Sized Pharmaceutical Companies (Highest CAGR Segment)
• Generic Pharmaceutical Companies
• Others

By Region

Pharmaceutical Contract Manufacturing Market Share 2025, (CAGR)

North America

36%

South America

xx%

Europe

28%

Middle East Africa

xx%

Asia Pacific

xx%

North America held the largest market share in 2025, backed by a dense base of innovator companies, biotech clusters around Boston, San Francisco and North Carolina’s Research Triangle, and large biologics and fill-finish campuses. The United States anchors the region, with sponsors adding domestic capacity to shorten supply chains and meet FDA cGMP expectations, while contract manufacturers compete on speed of technology transfer and sterile capacity. Canada contributes through vaccine, biologics and sterile injectable sites in Ontario and Quebec under Health Canada’s GMP framework, and Mexico serves as a cost-competitive base for finished dosage manufacturing and packaging that supports regional supply.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, supported by rapid capacity additions and a broad base of cGMP-compliant sites. China hosts large integrated CDMOs across small molecules, biologics and antibody-drug conjugates, and its marketing authorization holder system lets biotech owners outsource production more easily. India is scaling ingredient, formulation and biologics outsourcing, helped by production-linked incentives and a strong base of FDA-inspected sites. South Korea has become a hub for large-scale mammalian cell culture, while Japan contributes advanced bioprocess and fill-finish expertise, and competition on cost and quality is pulling global sponsors toward the region.

Countries and Regions Covered

Asia-Pacific (Fastest Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific

North America (Dominating Region)

• United States (Largest Country Market)
• Canada
• Mexico

Europe

• Germany (Largest Country Market)
• France
• United Kingdom
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The Pharmaceutical Contract Manufacturing Market is fragmented, with several hundred CMOs and CDMOs competing across small molecules, biologics, sterile injectables, oral solids and packaging, while a smaller group of global players such as Lonza, Thermo Fisher Scientific, Samsung Biologics, WuXi Biologics and Fujifilm lead high-value biologics and integrated programs. Key success factors include a clean regulatory inspection record, scalable capacity, technology platforms for complex modalities and the ability to offer development and commercial supply under one contract. Leading companies are prioritizing capacity expansion in the United States and Europe, investment in antibody-drug conjugate, peptide and fill-finish capabilities, and long-term supply agreements with large sponsors. Acquisitions of divested pharmaceutical plants and partnerships with biotech developers remain the main routes to add capacity and customers quickly.

Key Players

• Lonza Group (Switzerland)
• Thermo Fisher Scientific (US)
• Samsung Biologics (South Korea)
• WuXi Biologics (China)
• Fujifilm Corporation (Japan)
• Catalent, Inc. (US)
• Siegfried Holding AG (Switzerland)
• CordenPharma (Switzerland)
• Recipharm AB (Sweden)
• PCI Pharma Services (US)
• Piramal Pharma Limited (India)
• Syngene International (India)
• Sai Life Sciences (India)
• Divi’s Laboratories (India)
• Cambrex Corporation (US)
• Asymchem Laboratories (China)
• Pharmaron Beijing (China)
• Vetter Pharma (Germany)
• Aenova Group (Germany)
• Lotte Biologics (South Korea)

Recent Market Developments

• In September 2025, Fujifilm Biotechnologies opened its Holly Springs, North Carolina site, built with an investment above USD 3.2 billion. The first phase has eight 20,000-liter mammalian cell culture bioreactors, with a second phase of equal size planned, creating one of the largest commercial cell culture CDMO sites in North America.
• In December 2025, Samsung Biologics agreed to acquire GSK’s Human Genome Sciences biologics site in Rockville, Maryland for USD 280 million, and completed the transaction in the first quarter of 2026. The site has two cGMP plants with 60,000 liters of drug substance capacity and gives the Korean CDMO its first manufacturing base in the United States.
• In April 2026, ROIS, the CDMO arm of Spain’s ROVI, closed its acquisition of an injectable drug product manufacturing and packaging site in Phoenix, Arizona from Bristol Myers Squibb. The site includes an OEB5 high-potency area with commercial-scale lyophilization and extends ROIS from Europe into US sterile fill-finish contract manufacturing.
• In July 2026, Lonza announced an additional commercial-scale multi-purpose aseptic filling line for antibody-drug conjugates at its Stein, Switzerland site, expected to be operational in 2030 and backed by a long-term customer commitment. The investment reflects the shift of ADC programs toward integrated CDMO partners that handle both conjugation and sterile drug product.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is Pharmaceutical Contract Manufacturing?

2

What is the CAGR of the Pharmaceutical Contract Manufacturing Market?

3

Which service leads the Pharmaceutical Contract Manufacturing Market?

4

Which end user dominates the Pharmaceutical Contract Manufacturing Market?

5

Which dosage form has the highest market share?

6

What are the latest trends in the Pharmaceutical Contract Manufacturing Market?

7

Who are the end users of Pharmaceutical Contract Manufacturing?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates